{"filing":{"accession_number":"0001193125-26-234882","cik":"0001829802","ticker":"SNSE","company_name":"Sensei Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"d162035d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/d162035d8k.htm"},"events":[{"id":9436,"run_id":8275,"accession_number":"0001193125-26-234882","anchor_item_number":"8.01","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.45,"summary":"This disclosure announces an upcoming stockholder vote on the conversion of Series B Preferred Stock that would trigger a change of control under Nasdaq rules (\u003e20% dilution and control change per Rules 5635(a) and 5635(b)). However, the filing is pre-meeting notice rather than post-meeting results. The material substance is the announced change-of-control transaction requiring shareholder approval, which more closely aligns with ma_activity (change of control), though the Item 8.01 placement and focus on the voting mechanics creates ambiguity about the intended classification.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1078,"accession_number":"0001193125-26-234882","item_number":"8.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.45,"reasoning":"This disclosure announces an upcoming stockholder vote on the conversion of Series B Preferred Stock that would trigger a change of control under Nasdaq rules (\u003e20% dilution and control change per Rules 5635(a) and 5635(b)). However, the filing is pre-meeting notice rather than post-meeting results. The material substance is the announced change-of-control transaction requiring shareholder approval, which more closely aligns with ma_activity (change of control), though the Item 8.01 placement and focus on the voting mechanics creates ambiguity about the intended classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:19.977286+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1078,"accession_number":"0001193125-26-234882","item_number":"8.01","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.45,"reasoning":"This disclosure announces an upcoming stockholder vote on the conversion of Series B Preferred Stock that would trigger a change of control under Nasdaq rules (\u003e20% dilution and control change per Rules 5635(a) and 5635(b)). However, the filing is pre-meeting notice rather than post-meeting results. The material substance is the announced change-of-control transaction requiring shareholder approval, which more closely aligns with ma_activity (change of control), though the Item 8.01 placement and focus on the voting mechanics creates ambiguity about the intended classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:19.977286+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-05-21"}]}